ESRD

Global Hemodialysis Market Report 2022 to 2030 - Increasing Number of ESRD Patients is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 7, 2022
Medical Supplies, Medical Devices, Health, Diabetes, Managed Care, Biotechnology, PMP, Dialysis, Person, Hemodialysis, Government, International Diabetes Federation, ESRD, Kidney failure, Patient, Prevalence, Arteriovenous fistula, Chronic kidney disease, CKD, Incidence, Indian government response to the COVID-19 pandemic, Diabetes, COVID-19, Kidney, Hypertension, Fistula, IDF, USD, Medical device, Pharmaceutical industry

The global Hemodialysis market size is expected to reach USD 136.86 billion by 2030, according to a new study.

Key Points: 
  • The global Hemodialysis market size is expected to reach USD 136.86 billion by 2030, according to a new study.
  • The report gives a detailed insight into the current market dynamics and provides analysis on future market growth.
  • Renal failure and chronic kidney disease are becoming more common, which is one of the main drivers of market expansion.
  • Therefore, increasing ESRD prevalence is increasing the financial burden of kidney disorders globally and is a major driver of rising service revenue.

Taiho Oncology and Astex Pharmaceuticals Present Overall Survival Data for Oral Decitabine and Cedazuridine (INQOVI®, ASTX727) in Patients With MDS and CMML Harboring TP53 Mutations at 64th ASH Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Pneumonia, Intracranial hemorrhage, Society, Research, Toxicity, Anemia, Aplastic anemia, Child, Acute kidney injury, Ōtsuka, NCCN, Woman, Patient, Sepsis, MDS, Bone marrow suppression, Risk, CMML, Thrombocytopenia, Fatal, Microdeletion syndrome, MLF, International Prognostic Index, AUC, MOS, Birth, Febrile neutropenia, Clinical trial, National Comprehensive Cancer Network, Abstract, Neutropenia, Creatinine, ESRD, Pregnancy, De novo, Decitabine, Chronic kidney disease, TP53, Confidence interval, ASH, Mutation, Chronic myelomonocytic leukemia, Route of administration, Internal medicine, Sudden death, LFS, Kidney, Septic shock, Myelodysplastic syndrome, Vanderbilt University, Astex, Chromosomal deletion syndrome, IV, Fetus, Pharmaceutical industry, Birth control, Epidemiology, MD

PRINCETON, N.J. and PLEASANTON, Calif., Dec. 12, 2022 /PRNewswire/ -- Taiho Oncology, Inc. and Astex Pharmaceuticals, Inc. today announced preliminary data from the Phase 3 ASCERTAIN trial assessing overall and leukemia-free survival in adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML) harboring biallelic TP53 mutations following treatment with oral decitabine and cedazuridine (ASTX727). The data are being presented today as an oral presentation (Abstract #854) at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans.

Key Points: 
  • The data are being presented today as an oral presentation ( Abstract #854 ) at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans.
  • In the study, the population of patients harboring a TP53 mutation (44 of 125 patients) was characterized by allelic status: 14 patients had biallelic mutations and 30 patients had monoallelic mutations without other chromosomal deletions.
  • The primary endpoint of the study was total 5-day area-under-the-curve (AUC) equivalence of oral decitabine and cedazuridine and IV decitabine.
  • Astex, the Astex logo, Taiho Oncology, the Taiho Oncology logo and INQOVI are registered trademarks of Otsuka Holdings Co., Ltd. or its subsidiaries.

CHENMED RECOGNIZES TEAM MEMBERS WHO EMBODY VIP CARE AND INNOVATION

Retrieved on: 
Monday, December 12, 2022
95th Street, Attitude, Physician, Culture, Newsweek, ESRD, Patient, COVID, Medicare Part D coverage gap, Whitehall, Chronic kidney disease, Biemesderfer Executive Center, Medicare, Love, VIP, Training and development, Great Places, Growth, Multimedia, Shasta Regional Medical Center, Health, Health insurance, Auction, Hospital, Chenming Paper

MIAMI, Dec. 12, 2022 /PRNewswire/ -- ChenMed, one of the nation's leading providers of primary care focused on Medicare-eligible seniors, honored its exemplary team members at the third annual ChenMed Awards.

Key Points: 
  • MIAMI, Dec. 12, 2022 /PRNewswire/ -- ChenMed, one of the nation's leading providers of primary care focused on Medicare-eligible seniors, honored its exemplary team members at the third annual ChenMed Awards.
  • The winners represented several different ChenMed centers across multiple states, but all showed outstanding dedication to the company's mission, vision and focus on VIP care.
  • "The attitude and initiative of our team members are always so inspiring," said Stephanie Chen, chief legal and culture officer of ChenMed.
  • When ChenMed retains team members, it retains patients and ensures continuity of care.

Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

Retrieved on: 
Thursday, December 8, 2022
NIH, Immunoglobulin G, Kidney transplantation, Dialysis, ESRD, European Medicines Agency, Italian Medicines Agency, EMA, Patient, Cancer, DSA, Research, Hlas, Nasdaq Stockholm, Kidney disease, Degenerative disease, Medicine, Human leukocyte antigen, Veni, vidi, vici, Antibody, Survival, Kidney, Hansa, Medication package insert, State, Safety, Kidney failure, European, Chronic kidney disease, European Marketing Research Centre, Transplant, Risk, Dentistry, Pharmaceutical industry, Medical device, Agency

The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.

Key Points: 
  • The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.
  • By the time the body starts to synthesize new IgG, the patient will be receiving post transplant immunosuppressive therapy to reduce the risk of organ rejection.
  • Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

Retrieved on: 
Thursday, November 17, 2022
COVID-19, Degenerative disease, Diagnosis, ASN, American Society of Nephrology, BYU College of Life Sciences, Immunoglobulin A, FRCP, BK virus, Union, ESRD, Food, University, Autoantibody, Dialysis, Radar, Therapy, College, B-cell activating factor, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, TACI, Clinical trial, Cytokine, Biomarker, Surrogate, Coagulation, Chronic kidney disease, Standard of care, University of Leicester, Lupus nephritis, Society, International, Security (finance), B cell, Barratt, Research, BK, Kidney failure, Polyomaviridae, KOL, Vera, Pharmaceutical industry, Vaccine, IgA nephropathy

BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host a key opinion leader (KOL) webinar on IgA nephropathy (IgAN), a common cause of kidney failure. The webinar will be held on Monday, November 28, 2022 at 2:00pm ET.

Key Points: 
  • Recent data presented by Dr. Barratt at the American Society of Nephrology (ASN) Kidney Week 2022 showed atacicept reduced immune complex levels in patients with IgAN.
  • In addition, the Vera Therapeutics leadership team will provide an overview of the ongoing Phase 2b ORIGIN trial of atacicept in IgAN and the Companys pipeline.
  • If the data from the ORIGIN trial are supportive, Vera Therapeutics expects to initiate a pivotal Phase 3 clinical trial of atacicept in 2023.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study in patients with IgAN.

Tricida Announces Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
Diabetes, Pharmaceutical, Health, FDA, Workforce, Investment, Metabolism, Stifel, EGFR, Glomerular filtration rate, Patient, Metabolic acidosis, Research, Security (finance), Form 10-K, Annual report, Form 10-Q, Chronic kidney disease, CKD, ESRD, Kidney disease, Renewable energy, Pharmaceutical industry, Cryptocurrency

Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives.

Key Points: 
  • Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives.
  • Tricida has engaged Stifel and its wholly owned affiliate, Miller Buckfire, to serve as investment banking advisors and SierraConstellation Partners LLC to serve as a financial advisor.
  • The Company estimates aggregate costs of approximately $2.0 million, recorded primarily in November of 2022, related to one-time termination severance payments and other employee-related costs that will be paid during the fourth quarter of 2022 and the first quarter of 2023.
  • Financial Results for the Three and Nine Months Ended September 30, 2022
    Research and development expense was $19.9 million and $26.6 million for the three months ended September 30, 2022 and 2021, respectively.

The World's First ETa-specific Monoclonal Antibody: Gmax Biopharm's GMA131 Approved by the US FDA for Clinical Study on (DKD) Diabetic Kidney Disease

Retrieved on: 
Monday, November 14, 2022
DKD, Health, Kidney, Edema, IDF, Diabetes, Obesity, Chronic kidney disease, Extracellular matrix, G protein-coupled receptor, Proteinuria, US, ERA, PAH, Fibrosis, Eras, Trial of the century, Patient, Hypertensive emergency, Inflammation, Eta, Kidney disease, ESRD, ETB, IND, Pharmaceutical industry

announced today that its application of investigation of New Drug (IND) for GMA131 injection, the first global ETa-specific monoclonal antibody, was approved by the US FDA on Nov 11, 2022 for clinical study on diabetic kidney disease (DKD).

Key Points: 
  • announced today that its application of investigation of New Drug (IND) for GMA131 injection, the first global ETa-specific monoclonal antibody, was approved by the US FDA on Nov 11, 2022 for clinical study on diabetic kidney disease (DKD).
  • Dr. Shuqian Jing, Founder and Chairman of Gmax Biopharm, said, "GMA131 is the first genuine ETa-specific monoclonal antibody developed by Gmax Biopharm.
  • GMA131 is the same molecule as GMA301 which is currently in a Phase Ib trial of pulmonary arterial hypertension (PAH) in China/USA.
  • DKD, the leading cause of chronic kidney disease and end stage renal disease (ESRD), is one of the most important complications of diabetes.

KIDNEY GROUP INVITES 2023 MEDAL OF EXCELLENCE NOMINATIONS

Retrieved on: 
Wednesday, November 9, 2022
Taiwan Excellence Awards, MSN, Criterion, Social work, White House, American Board of Internal Medicine, MS, Congress, CMS, Patient, Kidney failure, Association, End Stage Renal Disease Program, Dialysis, U.S. Department of Labor, Office of Inspector General, ESRD, FMLA, CNN, Royal Canadian Legion Cadet Medal of Excellence, USMC, Health education, American Association, Medal, Nephrology, Program, American Board of Commissioners for Foreign Missions, Immunodeficiency, FAAN, DO, Kidney transplantation, Internal medicine, COVID-19, RN, Policy, FASN, Doctor of Philosophy, Transplant surgeon, Master of Science, History, Family and Medical Leave Act of 1993, Transplant, Kidney, Advancing American Kidney Health, Social media, Research, Awareness, Risk, Office of Inspector General, U.S. Department of Health and Human Services, FACP, Pharmaceutical industry, Medicine, MD, Dietitian

WASHINGTON, Nov. 9, 2022 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient organization in the U.S., has issued its call for nominations for its 2023 Medal of Excellence Award. The deadline for submissions is November 30, 2022. The AAKP Medal of Excellence Program elevates renal healthcare professionals in seven categories: Transplant Surgeon, Transplant Professional, Physician, Nurse, Social Worker, Dietitian, and Dialysis Technician.

Key Points: 
  • WASHINGTON, Nov. 9, 2022 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient organization in the U.S., has issued its call for nominations for its 2023 Medal of Excellence Award.
  • The AAKP Medal of Excellence Program elevates renal healthcare professionals in seven categories: Transplant Surgeon, Transplant Professional, Physician, Nurse, Social Worker, Dietitian, and Dialysis Technician.
  • Paul T. Conway , Chair of AAKP's Policy and Global Affairs and a 42-year kidney patient, stated, "The Medal of Excellence program is an extension of our national strategy to redefine high-quality kidney care based on the standards and needs of kidney patient consumers.
  • About the American Association of Kidney Patients (AAKP): AAKP was founded in 1969 by six dialysis patients determined to extend life-saving kidney treatments to every American at risk of kidney failure.

Global Dialysis Market Report 2022: Preference for Dialysis Over Transplants Driving Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
General Health, Health, Medical Devices, Co-production (public services), Awareness, Equipment, Kidney, Dialysis, Fresenius Medical Care, Growth, CAGR, Product-service system, Product, Chronic kidney disease, Population, Ageing, Incidence, Hypertension, Waste, Quality of life, Kidney failure, COVID-19, Stroke, Arthritis, US, Cardiovascular disease, Prevalence, ESRD, Diabetes, Peritoneal dialysis, Blood, Pharmaceutical industry, Medical device, Health insurance, Patient

The global dialysis market was valued at US$98.30 billion in 2021.

Key Points: 
  • The global dialysis market was valued at US$98.30 billion in 2021.
  • By End-User: The report provides an analysis of the market based on end-user: In-Center Dialysis and Home Dialysis.
  • The aging population is one of the main drivers of growth in the global dialysis market.
  • The key players in the global dialysis market are:
    Fresenius Medical Care AG & Co. KGaA

Modulim Announces Launch of Magnifi Clinical Workflow Software at Kidney Week 2022

Retrieved on: 
Thursday, November 3, 2022
Cloud, Patient, LAMP, HIPAA, Kidney disease, American Society of Nephrology, Kidney, Workflow, CA, Society, Magnifier (Windows), Data management, Ulcer, Standard of care, Assessment, Health, CEO, Chronic kidney disease, Moyamoya disease, Cancer, Risk, Nephrology, ESRD, Hospital, Technology, Ecosystem, Software, Data, Microangiopathy, Solution, Pharmaceutical industry, Medical imaging, Diabetes

IRVINE, Calif., Nov. 3, 2022 /PRNewswire/ -- Modulim, a health technology company that delivers point-of-care microvascular and data insights to save limbs and improve lives, announces the launch of Magnifi at American Society of Nephrology's Kidney Week 2022 in Orlando, FL, a software solution designed to empower clinicians with remote access to data insights and scalability to enhance clinical workflow across enterprises.

Key Points: 
  • The software solution takes a particular clinician's expertise and expands their impact and physical reach by enabling them to care for patients from anywhere.
  • "There are 61 million people in the US at risk for lower limb complications due to Diabetes, Kidney Disease, and Peripheral Arterial Disease.
  • Magnifi software utilizes the HIPAA compliant Modulim Cloud to securely and seamlessly sync with data captured by Clarifi.
  • Magnifi enhances clinical efficiency, improves workflow, and aides clinicians with scalable patient-centric software.